Reaction

Sleep Deficit reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,038 reports · 58 co-occurring drugs

As of the last recalculation, Sleep Deficit appears in 2,038 FAERS reports alongside 58 co-occurring drug terms. The strongest observed disproportionality signal is BRIVARACETAM (PRR 35.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Brivaracetam	31	35.7	35.9
Calcium, Magnesium, Potassium, And Sodium Oxybates	28	33.7	33.8
Ravulizumab	23	17.6	17.6
Tranexamic Acid	15	17.3	17.4
Cenobamate	11	13.5	13.5
Relugolix	28	12.3	12.3
Oxcarbazepine	33	10.5	10.5
Hyoscyamine Sulfate	9	10.0	10.1
Acetylcysteine	9	9.8	9.8
Amitriptyline Hydrochloride	16	9.4	9.4
Rotigotine	13	9.2	9.2
Guanfacine	7	9.1	9.1
Vibegron	7	8.9	9.0
Lacosamide	32	8.9	8.9
Clobazam	21	8.9	8.9
Hydrocodone Bitartrate And Acetaminophen	46	8.5	8.5
Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate	33	8.2	8.2
Pramipexole	12	8.0	8.0
Ozanimod Hydrochloride	6	7.4	7.4
Ropinirole	11	7.4	7.4
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, And Amphetamine Sulfate	25	7.3	7.3
Apalutamide	8	7.0	7.0
Aripiprazole Oral	27	6.7	6.7
Aripiprazole Orally Disintegrating	27	6.7	6.7
Elexacaftor, Tezacaftor, And Ivacaftor	8	6.6	6.6
Lithium	16	6.5	6.5
Lithium Bromatum	16	6.5	6.5
Levocetirizine Dihydrochloride	15	6.4	6.4
Eplerenone	8	6.4	6.4
Lisdexamfetamine Dimesylate	20	6.2	6.2
Naltrexone	18	6.0	6.0
Armodafinil	12	5.8	5.8
Eltrombopag Olamine	13	5.8	5.8
Sodium Oxybate	36	5.7	5.7
Nintedanib	17	5.6	5.6
Cariprazine	5	5.5	5.5
Asfotase Alfa	5	5.1	5.1
Lifitegrast	8	5.0	5.0
Mirabegron	18	4.8	4.8
Suvorexant	6	4.7	4.7
Methylphenidate	13	4.6	4.6
Tapentadol Hydrochloride	14	4.3	4.3
Brexpiprazole	6	3.7	3.7
Naltrexone Hydrochloride And Bupropion Hydrochloride	3	3.6	3.6
Fremanezumab-Vfrm	4	3.6	3.6
Esketamine Hydrochloride	6	3.4	3.4
Ofatumumab	11	3.4	3.4
Rimegepant Sulfate	4	3.2	3.2
Cannabidiol	7	3.1	3.1
Treprostinil	36	3.0	3.0
Abaloparatide	8	2.8	2.8
Galcanezumab-Gnlm	8	2.6	2.6
Sacubitril And Valsartan	28	2.5	2.5
Erenumab-Aooe	13	2.4	2.4
Nirmatrelvir And Ritonavir	12	2.3	2.3
Pimavanserin Tartrate	12	2.2	2.2
Dupilumab	74	1.6	1.6
Tirzepatide	24	1.5	1.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.